Cardiac remodelling and RAS inhibition - Wikidata - wikimedia - TriplyDB

Cardiac remodelling and RAS inhibition

Cardiac remodelling and RAS inhibition

http://www.wikidata.org/entity/Q28076749

about

New Treatment Strategies for Alcohol-Induced Heart Damage Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Angiotensin converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Gene expression and gene associations during the development of heart failure with preserved ejection fraction in the Dahl salt sensitive model of hypertension.Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2.The Potential Role of Oxidative Stress in Cardiac Hypertrophy: A Narrative Review.Chymase-dependent production of angiotensin II: an old enzyme in old hearts.NF-κB inhibitor on Toll-like receptor 4 signal-induced expression of angiotensinogen and AT1a receptor in neonatal rat left ventricular myocytes

P2860

Q28078093-A5759DEC-E968-4DF2-AAAB-68513C9EC9D8 Q30235583-591E9849-AD06-4E1F-AD07-C5CF6E583661 Q38612115-76BB83AE-2751-43AD-8938-C47008D4FBA6 Q38750210-D5C32274-317F-4771-8D77-034F88D5DDF1 Q47400069-E7D9D330-C397-462C-802F-75022F8B5939 Q47685507-5A8C7710-43B1-4A4B-9517-D8CA52A88BED Q50052210-702158A3-783E-4659-A6D2-70DA2FC14E76 Q51343625-3B8A58A8-341B-4D9A-8753-618EB2E4536D Q57787074-A16DB489-B3BC-4DC8-A351-8AA85F7846C5

P2860

Cardiac remodelling and RAS inhibition

http://www.wikidata.org/entity/Q28076749

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Cardiac remodelling and RAS inhibition

@ast

Cardiac remodelling and RAS inhibition

@en

Cardiac remodelling and RAS inhibition

@nl

type

label

Cardiac remodelling and RAS inhibition

@ast

Cardiac remodelling and RAS inhibition

@en

Cardiac remodelling and RAS inhibition

@nl

prefLabel

Cardiac remodelling and RAS inhibition

@ast

Cardiac remodelling and RAS inhibition

@en

Cardiac remodelling and RAS inhibition

@nl

P1433

Q28076749-36FAD648-EB8E-41D9-A8B4-DAEB4D136D6E

P1476

Q28076749-F5E41C0E-1BC2-4987-B434-C5BA66361852

P2093

Q28076749-6D2BB9AF-916C-49D5-8805-BD9079A9A6D1

P2860

Q28076749-04676EAB-075B-47FC-BFFD-A49E6667F1C6

Q28076749-082428D0-D1B3-4155-AC2F-CB463E053AE3

Q28076749-09F45A5C-7328-480B-8A27-69D63C4D4316

Q28076749-0AC1999C-4CA7-4B8C-A7A2-83CF4568C2EA

Q28076749-10E3F4EA-2194-4F3D-81A3-7CADFF23508B

Q28076749-10F1E6B1-A938-476A-93F6-63BBCDA7603E

Q28076749-1C9D5B23-37EE-45FE-B8C5-9163E8661AF8

Q28076749-1DC4E0C7-F3E4-4BF1-A0E5-4F5A45240C16

Q28076749-24C61776-CA8A-4657-90EF-6B6F3E2D6CC0

Q28076749-3E23995B-534A-4D45-A693-793E13E4E817

P304

Q28076749-EADFD9C5-E743-4E05-9011-103DC31C9D46

P31

Q28076749-42A43ED0-118E-4063-A465-6CC727DC96A3

P3181

Q28076749-6435F490-B150-4DAE-A0B6-C7B577FC9A67

P356

Q28076749-8E1537B8-138F-41A7-94FB-E9CA57F60B04

P407

Q28076749-099EA963-B987-4D12-8100-3C4929B7C3B2

P433

Q28076749-46201D1B-2E0E-47DA-9810-188534F9695C

P478

Q28076749-8A34DD95-496A-48AA-AAA6-14B2CD6E1E51

P577

Q28076749-AC17FD80-EA79-4D88-8C85-8B3A8F1D8C13

P698

Q28076749-0D4A5081-C5D9-405E-AD2A-169076AEEE53

P932

Q28076749-6492A68E-DF1D-4491-B126-58F543057611

P3181

P356

1753944716642677

P1433

Therapeutic advances in cardiovascular disease

P1476

Cardiac remodelling and RAS inhibition

@en

P2093

C. M. Ferrario

http://www.w3.org/2001/XMLSchema#string

P2860

Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function

An evolving story of angiotensin-II-forming pathways in rodents and humans

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure

Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue.

P304

162-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3271804

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1753944716642677

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27105891

http://www.w3.org/2001/XMLSchema#string

P932

5192558

http://www.w3.org/2001/XMLSchema#string